Pharmaceutical - Markets & Marketing, Eylea


Current filters:

Markets & MarketingEylea

Popular Filters

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments


Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report


Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Strong uptake of Regeneron/Bayer wet AMD drug Eylea in USA, but Avastin still leads


The majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal…

AllerganAvastinBayerBiotechnologyEyleaFovistaLucentisMarkets & MarketingNorth AmericaOphthalmicsOphthotechPharmaceuticalRegeneronRoche

Avastin remains preferred DME therapy, despite Lucentis extended label in USA


Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Recent Eylea growth in USA appears to be coming from expanded uptake among prescribers


After one year on the market, 86% of US retinal specialists have prescribed Regeneron's (Nasdaq: REGN)…

BayerBiotechnologyEyleaMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneron

Novartis' Lucentis captures two-thirds of wet-AMD patient share in Europe


Retinal specialists in the EU5 (France, Germany, Italy, Spain and the UK) treat 66% of intravitreal-pharmaceutically-treated…

AvastinBayerBiotechnologyEuropeEyleaLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalRoche

Eye disorders drug sales set to reach $23.8 billion in 2016, predicts Visiongain


Total worldwide revenues from drugs to treat eye disorders will reach $23.8 billion in 2016, according…

EyleaGlobalMarkets & MarketingOphthalmicsPharmaceuticalRegeneron

Trial and uptake of Regeneron's Eylea continues to rise among US retinal specialists; report


After six months on the market, 76% of retinal specialists in the USA have prescribed US biotech firm…

AvastinBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Santen to co-promote Bayer and Regeneron's Eylea in Japan


German drug major Bayer's (BAYN: DE) Japanese subsidiary, Bayer Yakuhin, and Santen Pharmaceutical (TYO:…

Asia-PacificBayerEyleaLicensingMarkets & MarketingOphthalmicsPharmaceuticalRegeneronSanten Pharmaceuticals



Back to top